F. McClanahan

发表

Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo

J. Gribben, P. Lichter, A. Benner, 2016, Leukemia.

Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes

J. Gribben, Anuradha Tarafdar, A. Michie, 2015, Haematologica.

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

A. Krämer, A. Ho, A. Benner, 2011 .

LYMPHOID NEOPLASIA Mechanisms of PD-L1/PD-1 – mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E m -TCL1 CLL mouse model

J. Gribben, D. Neuberg, C. Croce, 2015 .

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

A. Ho, K. Lisenko, T. Dittrich, 2016, BMC Cancer.

Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma

A. Ho, M. Witzens‐Harig, F. McClanahan, 2013, Cancer.

Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.

J. Gribben, D. Neuberg, C. Croce, 2014, Blood.

Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia - Still a Valid Treatment Option, or is the Game Over?

P. Dreger, F. McClanahan, 2012, Mediterranean journal of hematology and infectious diseases.

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.

N. Schmitz, G. Brittinger, H. Döhner, 2012, Blood.

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma

T. Hielscher, A. Krämer, A. Ho, 2012, American journal of hematology.

Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.

J. Gribben, D. Neuberg, C. Croce, 2014, Blood.

RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics

K. Bennett, J. Gribben, J. Orange, 2016, Nature Immunology.

Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?

J. Gribben, F. McClanahan, 2014, Hematology/oncology clinics of North America.

Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

J. Gribben, T. Sharp, F. McClanahan, 2016, Haematologica.

Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

J. Gribben, D. Neuberg, C. Croce, 2015, Blood.

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.

J. Gribben, P. Lichter, M. Seiffert, 2015, Blood.

Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab‐CHOP immunochemotherapy with and without consolidating radiotherapy

K. Herfarth, T. Hielscher, A. Ho, 2010, European journal of haematology.

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

J. Gribben, S. Iqbal, A. Ramsay, 2013, Blood.

Overcoming Immunodeficiency in Chronic Lymphocytic Leukaemia: Current Knowledge and Perspectives

J. Gribben, F. McClanahan, 2014, EMJ Hematology.

The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

J. Gribben, F. McClanahan, 2018, Handbook of Immunosenescence.

Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

A. Krämer, A. Ho, A. Benner, 2015, British journal of haematology.

New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.

J. Gribben, F. McClanahan, 2015, Clinical advances in hematology & oncology : H&O.

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Lisa L. Smith, R. Ulrich, J. Byrd, 2016, Clinical Cancer Research.

REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK

Victoria M Wright, Valentina Abet, J. Emmerich, 2016 .

Investigating and reversing T-cell dysfunction in the Eμ-TCL1 mouse model of chronic lymphocytic leukaemia (CLL)

F. McClanahan, 2015 .

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

N. Schmitz, H. Döhner, M. Hallek, 2009 .

Targeting dysfunctional myeloid cells delays disease development and improves immune function in a CLL mouse model (TUM6P.1009)

J. Gribben, P. Lichter, V. Kalter, 2014, Journal of Immunology.

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

K. Herfarth, T. Hielscher, M. Hensel, 2009 .

Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology

H. Goldschmidt, B. Stieltjes, F. Laun, 2011, British journal of haematology.

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)

R. Brand, M. Hallek, S. Stilgenbauer, 2010 .

Allogeneic Transplantation for Chronic Lymphocytic Leukemia in the Age of Novel Treatment Strategies.

J. Gribben, F. McClanahan, M. Schwarzbich, 2016, Oncology.

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals

H. Goldschmidt, B. Stieltjes, H. Schlemmer, 2011, Acta radiologica.

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.

J. Gribben, P. Lichter, M. Seiffert, 2015, Blood.

Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology

H. Goldschmidt, B. Stieltjes, F. Laun, 2011, British journal of haematology.

Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7

J. Gribben, C. Croce, N. Zanesi, 2014 .

Immunotherapeutic approaches have the potential to brighten the future not only for patients with del(17p13.1), but for all CLL patients.

J. Gribben, F. McClanahan, 2012, Oncology.